Raphael Wisniewski

Raphaël Wisniewski is a Partner at Andera Partners on the andera Life Sciences team. Andera says he joined the firm in 2001 and has worked on numerous investments, M&A transactions and IPOs since then, with experience across both banking and venture capital.

Before Andera, Wisniewski spent seven years in London in healthcare and investment banking. He first worked in the finance department of Générale de Santé International in London, where he held treasury and investment-analysis roles, then moved into the healthcare groups of Salomon Smith Barney from 1996 to 1999 and Goldman Sachs from 1999 to 2001.

His transaction background spans pharmaceuticals, medical devices, biotechnology and services companies. At Andera, he has served on the boards of EG 427, SoniVie, ImCheck, Grey Wolf Therapeutics, Artios, AM Pharma and Exciva; prior board roles include Amolyt Pharma, ReViral, Axonics Modulation Technologies, Novagali Pharma, Pangenetics, Chase Pharmaceuticals, Oncoethix and Vessix Vascular until acquisitions by pharmaceutical or medical-device companies.

Wisniewski graduated from HEC in 1993 and received a master’s degree in Applied Economics from Institut d’Etudes Politiques in 1994.

• Invests through andera Life Sciences in companies developing breakthrough therapeutic products and medical technologies “from preclinical stages to commercialisation.”
• Targets companies where innovation is based on strong science, robust preclinical or clinical evidence, and defensible intellectual property.
• Focuses on Europe and the United States, with company stages ranging from start-up/early-stage to growth/late-stage.
• Typical andera Life Sciences equity investment size is €15 million to €60 million per company.
• Andera says it takes an active role in investments, backing entrepreneurs to take innovations to major value-inflection points.
• Wisniewski’s quoted investment rationale often emphasizes differentiated technology, unmet medical need, experienced teams, and a credible path to clinical and commercial success.